>>live from Las Vegas. It's the Q covering AWS executive. Something brought to you by extension. >>Welcome back, everyone to the cubes. Live coverage of the ex Censure Executive Summit here in AWS. Reinvent I'm your host, Rebecca Knight. We have three guests for this segment. We have Fang Deng. She is the big data and an Advanced Analytics program. Lead analytic Seo hee at Novartis. Thank you so much for coming on the show. Thank you. We have low eq zero. He is Novartis head of Analytic Seo Hee. Thanks so much. Look, and Vika sinned. Wan Hee hee is applied intelligence delivery lead at Accenture. Thank you so much. Thank you. So I want to start with you. Look, no. Novartis, of course, is a household name. It's one of the largest pharmaceutical companies in the world. But that left you to just walk our viewers a little bit through your business and sort of the pain points you were looking to solve with this journey Thio to the cloud >>you think you ever care? So I think if I if we look at the company, I think Wayne realized that it is more and more difficult to bring new trucks to market, so it takes about 12 years and on $1.2 billion to find a new trick. So at the same time, we see that there's more and more patient that need access to medicines. So in the last two years, I think we tried toe clear the new strategy where we're trying to re imagine medicine for user's data and technology. So in 2018 we've recruited a new studio that's came and I tried to build a digital ambition which is around fabulous, which is the innovation, the operation and the engagement on the innovation. What we're trying to do is to find new compound, will application off existing compounds into our business, make sure that I think patients can get access to drugs much faster and earlier on in the operation. We are trying to optimize the backbone off day to day processes, beat in the manufacturing or in the supply chain, or in the commercialization to ensure that the patient also get access to that much faster in the engagement. We're trying to healthy a cheapie and the players and then the and the patients to better understand the tracks reproduce as well as on the medication they need to have to receive treatment. So if you look at these three pillars, the cloud strategy is an essential portion of it. Because in all of its processes we have a lot of data and full cloud. I think we can make use off his data to help to innovate, open, right and engage. >>So as you as you said, it's really about reimagining medicine. I mean, from the drug discovery process to how it's helping patients live, live longer, healthier lives. Thanks. So talk about the vision for the Formula One platform. >>Yeah, aside, like a mission before we trying to re imagine our products for the patient. And we're trying to use more the more data history data and also the public data try to support our products. And the Formula One is our future enterprise data and the next perform for our new artists. So our objective is trying to love you all the new technology and also trying to consolidate over data in our Macleod and build up this platform for the whole notice Users support our business, do better products full patient. >>So when it comes to these these new new platforms, new technologies that are being introduced. We know that oftentimes the technology is the easy part. Or at least the more straightforward part I should say. But it's it's sort of getting people on board the change management. What are some of the challenges that you that you know of artists faced in terms of of the culture and the skills for your for your workforce? >>So if you look at that, the are in disgrace, very traditionally nature. And when we embarking the details confirmation, I think the first thing we had to change the culture of the company. So when you when you listen to our CEO, I think you tried to promote this invoice culture where all of us are Syrian leaders. And then we walk, you know, as a thing as an organization where we try to help each other and more and more collaborate when it comes to digital transformation. When we started this having this period, we've realised actually that workforce was not trained, so the first few things that we did disease is a tight wire new workforce, but also try to actually identify the advocate ambassadors. I could go and then go into residual confirmation early on to be able to help and to guide the office to get for that. So it's actually it's totally immaterial, Johnny. And then we are now in the second year and we've seen already a tremendous four guys, right? >>Can you describe some of the changes that you've seen him? I mean, I'm really interested in what you talk about. The ambassador's, the people who are going to spread the good word. What are what are some of the changes that you've seen in your workforce? Yeah, we can mention >>that. It's like you mentioned before. Um, like, talking about regarding overall catch a bus back to tried to leverage a new attack. Knowledge like the delivery perspective. We trying to do more automation, and the May 1 side is trying to get more efficiency and also another side. Try to ensure the intern responsibility for one product to be produced and also at the same time, let me through more automation to think about this secret inside the compound inside. Help us a lot of in pulling that part also, because >>maybe I can compliment that so I think if you look at it when the initial studying part of our journey, I think that a lot of people were reluctant to go and then tie to work on a cloud and to work with digital technology. So we found few projects where we felt there's a good ready for money. And as we can deliver fast in fact, Andi to things like, I don't get reviewed t piece every. Make sure that when we went, our field falls, go then and talk to the hippies. They know what to talk about an orphan, and then which format. We also look at that we can reduce costs internally and for the food, different projects and then on product that we've established, we build credibility within the organization that helped to disseminate the cultural transformation. >>So once others air seeing, seeing the benefits that that captured, they're more likely to to feel good about the cloud work. >>Yeah, that's that's the true and also notes of the news. Things like our teams, they are interesting about that. You see more and more people talking about our driveway and also talk about the UAV's and how can we improve the did he re efficiency and the same time is come back to say that teams think about how to make themselves to be a product owner and the product the way of the great. Let's the glistening for the whole team >>because I want to bring you in here a little bit. So talk to me about how ex Center is helping Novartis, particularly in in this eight of us. Caught initiative. >>Six incher is a leader in business and technical i t transformation programmes. So what we're bringing on the table is in the expertise with not only the technology and the AWS elements, but also the business and technical transformation expertise that have we have over the years in the firm. On additionally, I think you know, it's not only about technology change. As you mentioned, it's all a lot of change and operating model and and also kind of working with a very blended team. Across that expertise and experience is what you bring to the table >>a blended team, culturally, regionally, actually, all of it >>one of that belief. I mean, just to give an example. We are working across steams in roughly about six geography ese from various cultures. Where's countries? And it's it's, ah, various time zones, which makes it quite challenging to make it all work together. So you started the journey. I hope you succeed in it. And, uh, you know, it's working well, so far, >>so Cloud is is really a megatrend right now. What are the differences that you're seeing across Regions, countries, industries? >>So I think it's this many answers many parts of the answer to the question. So I think if I talk about, um, industries So you know, initially when clouds started, we had seen a major up take off the cloud technology and the company that manufactured the clown technology and telecommunications, and you know where the older infrastructure and technology aspects were, Whereas companies like health care and media and metals and mining, We're kind of behind the curve in adoption rates because off their respective, you know, concerns around compliance and security of data. But I think that trends is slowly shifting. US. Companies are becoming more open. I think I've seen how the public cloud has matured. The security models, you know, are speaking for themselves. People can understand the benefits from moving to the cloud in terms off, you know, cost rationalization from producing maintenance costs, focusing their proteins on things that they were not able to divert their attention on. >>The fact we had, I think I will say for me and then where I've seen a Novartis if it is access to innovation. So I think loud offering brings a lot off innovation at happy face. That's one hand and also access to extend our collaboration. So when you're in, you know, inside focus I think the relatives from over there wants to walk and collaborate with you. But when you work on the cloud, everybody goes on the cloud. So that's really a stream manifested ate a collaboration with Nextel Partners. >>So how is that changing the culture of Novartis itself? In terms of there, there are more opportunities to collaborate. And it also is maybe changing the kinds of workers you attract because it is is people who want to be doing that in their day to day. >>Well, if you look at it, um, in the past, I think we used to have our own workforce, and then we tried to do a lot of things with our own workers, but I think he's in the on Monte. Workers are full of us, so we have more and more partnerships being announced, and this publishing, I mean used actually to help the company to in revenge himself. So that's actually on one hand on the other side. As you said, I think that to attract with talents I think you need. You also need to have a different future. But you need also to be able to give them the flexibility to work and do the things they like, and we're in a context and a framework. >>One of the things that we hear about so much at the's technology conference is this buzzword of digital transformation and of artisans obviously embarking on its own digital transformation as well as his journey to the cloud. There happen. They're powering each other, they're accelerating each other. How would you describe what is happening to the industry and to know Vargas with it within this, the pharmaceutical industry? >>Yeah, I think, based on our knowledge, to send the why this may be the first. The company can't be trying to build this kind of enterprise level data and also an Alex platform, and based on that, we will be able to counseling date off the history potato intended date on public date, huh? And the Human Industry Day. Then they tried to help us to produce the better products for the patient the same time it gave also the team a chance as you mentioned before, and the look at former more opportunities and the China to leverage in your technology particles of Kayla. >>It's also changed the way that we work every day. So if you look at it now, um, we won't be virtual assistant. We I think we use machine learning elements politics to be able to talkto you are a cheap piece. We actually monitor clickers, Kyle real time having using common centers. So every single day, I think the use off, digital at work and atom in the physical man thinks. And I think we have seen that the adoptions has increased since we have I ever to launch successful products. And I think >>one of the things which, which I really like about working in the bodies, is also I think there's there's an ambition to drive business value quickly. So you know you take a very agile use case, best approach on things rather than having to wait for very long years of time. Plus, the company kind of encourages a culture which is based on mutual cooperation and sharing knowledge, which is great >>because Novartis is really on the vanguard of companies in terms of how much it's embraced, the cloud and how much it's using it. What do you think? Other companies, pharmaceutical companies, but maybe even in other industries as well could learn from the nerve artists example. >>I think one thing people really shy about is, you know, when they moved to the cloud is the security aspect. I think what people probably had failed to realize in the past that there's been so much developments on security in the public cloud, which has bean key focus areas, something nobody's has taken the challenge and has understood that very well. And I think companies can learn from all the different aspects of security that you know were built into our entire transformation work, starting from ingesting data, the user management to access and all of that thing, so that's kind of one thing. Similarly, compliance related aspects as well, you know, So we've g x p compliance is at the core off how we're building our solution. So I think on dhe, if you understand how we built the rules around compliance. But in architecture, I think couples can learn from that a swell and build that is integral part off your not only technology solution, but the process that goes along with it. >>We started our conversation talking about Novartis and its quest to reimagine medicine. How How do you think that your industry is gonna look 5 10 years from now? I mean, the drug discovery process is slow on purpose. I mean, we need to think of patient health and safety for most. But how do you think it really could change the course of how we treat people? >>If if you look at it is more and more treatment required that actually I used and required data as a service or are being actually process for data. So when I am, when we look at the things the way that the industry is changing, I think the times to develop drugs, yes, takes longer. But I think for your use off the data that you have. I think you can try to reduce I cycle. So one of the objective is to reduce the cycle by one firm. Between that, we could bring the day. Is a new director market in eight years, rescues 12 years Today. The other thing is that way for user's data. You can monitor them patient, and you can recommend it the treatment of 80% off foundation. They don't go in and finish her treatment. So I think if we can show the audience to treatment, then there's a lower risk off the admissions to the season and sickness that they have. >>So it's not even not not just Novartis seeing the value of the date. It's the patients themselves, efficiency >>and the d. A r C as well, right? Because I think if you're if the situation is not six and I think the insurance doesn't have to pay. So I think all the value chances is being comes from >>well, sang Loic, because thank you so much for coming on the Cube. It was a really fascinating segment. Thank you. I'm Rebecca night. Stay tuned for more of the cubes. Live coverage of the Ex Center Executive Summit coming up in just a little bit